Rituximab Biosimilar

About Hansoh Pharma

Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a vertically integrated pharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company has built a strong portfolio of generic drugs, particularly in the US market, while also investing in complex generics, biosimilars, and proprietary drug development. With manufacturing facilities across multiple countries and a global workforce, Dr. Reddy's continues to expand its market presence through strategic partnerships, acquisitions, and new product launches. The company is publicly traded on both Indian stock exchanges and NASDAQ, reflecting its status as a major player in the global pharmaceutical industry.

About Changchun High-Tech Industry

Changchun High-Tech is a prominent, revenue-generating biopharmaceutical enterprise in China, primarily known for its vaccine business. Its strategic position is anchored by its controlling stake in Changchun BCHT Biotechnology, a critical supplier of the Varicella vaccine in the domestic market. The company leverages this established commercial foundation to invest in and develop a broader pipeline of biological products, including monoclonal antibodies and other innovative therapeutics. As a publicly listed entity, it operates with a diversified business model that also includes investments in real estate and other industries.

Therapeutic Areas

Other B-cell Lymphomas Drugs